Circulating Tumor DNA Testing for Homology Recombination Repair Genes in Prostate Cancer: From the Lab to the Clinic

Approximately 23% of metastatic castration-resistant prostate cancers (mCRPC) harbor deleterious aberrations in DNA repair genes. Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) therapy has shown improvements in overall survival in patients with mCRPC who harbor somatic and/or germline altera...

Descripción completa

Detalles Bibliográficos
Autores principales: Cimadamore, Alessia, Cheng, Liang, Massari, Francesco, Santoni, Matteo, Pepi, Laura, Franzese, Carmine, Scarpelli, Marina, Lopez-Beltran, Antonio, Galosi, Andrea Benedetto, Montironi, Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197269/
https://www.ncbi.nlm.nih.gov/pubmed/34073818
http://dx.doi.org/10.3390/ijms22115522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197269/
https://www.ncbi.nlm.nih.gov/pubmed/34073818
http://dx.doi.org/10.3390/ijms22115522

Ejemplares similares